Medindia

X

Vibativ's Delayed Approval for Nosocomial Pneumonia Will Significantly Reduce Its Commercial Impact in the Methicillin-Resistant Staphylococcus Aureus Drug Market

Thursday, February 18, 2010 General News J E 4
Advertisement
In 2018, Vibativ Will Garner Less Than Half of What it Had Been Previously Forecasted to Earn, According to New Findings from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Gisselle Morales

Christopher Comfort

781-296-2691

781-296-2597

gmorales@dresources.com

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Stelara Impresses With Efficacy Data and Dosing Co...
S
Approval in Japan of New Formulation of Mitsubishi...